Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.

MLA

Burmester, Gerd, et al. “Efficacy and Safety Results from a Randomized Double-Blind Study Comparing Proposed Biosimilar ABP 798 with Rituximab Reference Product in Subjects with Moderate-to-Severe Rheumatoid Arthritis.” Clinical Rheumatology, vol. 39, no. 11, Nov. 2020, pp. 3341–52. EBSCOhost, https://doi.org/10.1007/s10067-020-05305-y.

APA

Burmester, G., Drescher, E., Hrycaj, P., Chien, D., Pan, Z., & Cohen, S. (2020). Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis. Clinical Rheumatology, 39(11), 3341–3352. https://doi.org/10.1007/s10067-020-05305-y

Chicago

Burmester, Gerd, Edit Drescher, Pawel Hrycaj, David Chien, Zhiying Pan, and Stanley Cohen. 2020. “Efficacy and Safety Results from a Randomized Double-Blind Study Comparing Proposed Biosimilar ABP 798 with Rituximab Reference Product in Subjects with Moderate-to-Severe Rheumatoid Arthritis.” Clinical Rheumatology 39 (11): 3341–52. doi:10.1007/s10067-020-05305-y.